PRIMARY OBJECTIVES:~I. To determine the primary pharmacodynamic effect of wee1 inhibitor ZN-c3 (ZN-c3) in tumor biopsies from patients with advanced triple-negative breast cancer (TNBC) and ovarian cancer.~II. To assess safety and tolerability of the proposed therapy.~SECONDARY OBJECTIVES:~I. To assess clinical benefit of TNBC and ovarian cancer patient from the proposed therapy.~II. To determine time to disease progression. III. To assess participant survival on study.~EXPLORATORY OBJECTIVES:~I. To evaluate ZN-c3 pharmacokinetics (PK). II. To identify predictive biomarkers of sensitivity to therapy. III. To identify emerging mechanisms of resistance to therapy.~OUTLINE:~Patients receive Wee1 inhibitor ZN-c3 orally (PO) once daily (QD) on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up every 6 months for to 1 year.
This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced). ZN-c3 is an enzyme inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.